| Stephen J Pollard, MD | |
|
9800 Shelbyville Rd, Suite #220, Louisville, KY 40223-2992 | |
| (502) 429-8585 | |
| (502) 429-6157 |
| Full Name | Stephen J Pollard |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 47 Years |
| Location | 9800 Shelbyville Rd, Louisville, Kentucky |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629077698 | NPI | - | NPPES |
| 30004910 | Other | RAILROAD | |
| 100148710 | Medicaid | IN | |
| 64186158 | Medicaid | KY | |
| 1049052 | Other | KY | PASSPORT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207K00000X | Allergy & Immunology | 01026960A (Indiana) | Secondary |
| 207K00000X | Allergy & Immunology | 18615 (Kentucky) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Health Louisville | Louisville, KY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Psf Pllc | 1557265543 | 98 |
| Psf Pllc | 1557265543 | 98 |
News Archive
A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory deaths, but the other - which is prescribed in the majority of cases - increases respiratory deaths.
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use NewCardio's QTinno(TM) software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
› Verified 5 days ago
| Entity Name | Psf Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1881785947 PECOS PAC ID: 1557265543 Enrollment ID: O20031121000240 |
News Archive
A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory deaths, but the other - which is prescribed in the majority of cases - increases respiratory deaths.
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use NewCardio's QTinno(TM) software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Stephen J Pollard, MD 9800 Shelbyville Rd, Suite #220, Louisville, KY 40223-2992 Ph: (502) 429-8585 | Stephen J Pollard, MD 9800 Shelbyville Rd, Suite #220, Louisville, KY 40223-2992 Ph: (502) 429-8585 |
News Archive
A new study has demonstrated that a protein called Niemann-Pick C1 (NPC1) is critical for the Ebola virus to infect a host. The study, published in the May/June issue of mBio, the online open-access journal of the American Society for Microbiology, suggests that drugs that block NPC1 could be used to treat this deadly disease.
Brown was diagnosed with COPD and emphysema, the third leading cause of death in the United States, only behind heart disease and cancer. Right now, the only studied interventions that prolong life for patients with severe COPD are supplemental oxygen in people with low oxygen levels and lung volume reduction surgery (LVRS) in appropriately selected individuals. Like most COPD patients, Brown was given medication but told there was no cure. He was 58 years old.
A new analysis that compares two common inhalers for patients suffering from chronic obstructive pulmonary disease (COPD) finds that one reduces respiratory-related hospitalizations and respiratory deaths, but the other - which is prescribed in the majority of cases - increases respiratory deaths.
NewCardio, Inc., (OTC Bulletin Board: NWCI) a cardiac diagnostic and services company, today announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use NewCardio's QTinno(TM) software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.
The U.S. Food and Drug Administration (FDA) this week provided the necessary authorization for clinical trials of chloroquine and hydroxychloroquine for the treatment of the novel coronavirus. These two drugs have been claimed by President Donald Trump to be a potential treatment for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which causes COVID-19 disease. To date, there has been no conclusive proof regarding the safety and efficacy of these drugs in COVID-19 cases, say officials.
› Verified 5 days ago
Dr. Derek A Damin, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 163 South English Station Road, Louisville, KY 40245 Phone: 502-882-2063 Fax: 502-882-2067 | |
David E Pallares, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9800 Shelbyville Rd Ste 220, Louisville, KY 40223 Phone: 502-429-8585 Fax: 502-429-6157 | |
Ronald Peter Moyer, MD Allergy & Immunology Medicare: Not Enrolled in Medicare Practice Location: 4402 Churchman Ave, Louisville, KY 40215 Phone: 502-361-9935 Fax: 502-361-9950 | |
Dr. Daniel P Garcia, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9113 Leesgate Rd, Louisville, KY 40222 Phone: 502-426-1621 Fax: 502-426-7906 | |
Timothy A Feger, MD Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9800 Shelbyville Rd, Suite #220, Louisville, KY 40223 Phone: 502-429-8585 Fax: 502-429-6157 | |
Natalie Beaven Miller, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9800 Shelbyville Rd, Suite #220, Louisville, KY 40223 Phone: 502-429-8585 Fax: 502-753-0889 | |
James W. Sublett, M.D. Allergy & Immunology Medicare: Accepting Medicare Assignments Practice Location: 9800 Shelbyville Rd, Suite #220, Louisville, KY 40223 Phone: 502-429-8585 Fax: 502-429-6157 |